Key result
Elevation of four NLRP3-related biomarkers is linked to ~2.6-fold higher risk of major cardiovascular events.
Why the study?
The predictive value of individual and combined NLRP3 inflammasome pathway-related biomarkers for long-term cardiovascular risk in multivessel disease patients remains to be systematically evaluated.
Do combined elevated levels of NLRP3-associated inflammatory biomarkers predict increased risk of long-term major adverse cardiac and cerebrovascular events in patients with multivessel coronary artery disease?
Cohort (n=1,058)
Yes
Do combined elevated levels of NLRP3-associated inflammatory biomarkers predict increased risk of long-term major adverse cardiac and cerebrovascular events in patients with multivessel coronary artery disease?
Answers are grounded in this paper and cite their sources.
Combining multiple upstream and downstream inflammatory biomarkers of the NLRP3 inflammasome pathway improves cardiovascular risk stratification in patients with multivessel disease beyond hsCRP alone.
BACKGROUND: Inflammation plays a crucial role in adverse outcomes of coronary artery disease. NOD-like receptor family pyrin domain-containing protein 3 (NLRP3) inflammasome activates 2 classical pathways: interleukin-1β (IL-1β)/IL-6/high-sensitivity C-reactive protein (hsCRP) and IL-18/IL-6/hsCRP. However, the predictive value of pathway-related biomarkers, particularly their combinations, remains to be systematically evaluated. OBJECTIVES: The authors aimed to explore the predictive value of individual and combined biomarkers from 2 pathways for long-term cardiovascular risk in patients with multivessel disease (MVD). METHODS: From a prospective, multicenter cohort, 1,058 consecutive patients with MVD were enrolled. The primary endpoint was major adverse cardiac and cerebrovascular event (MACCE-4P), a composite of all-cause death, myocardial infarction, revascularization, and stroke. RESULTS: During a median 2-year follow-up (IQR: 2.0-2.1 years), 130/1,058 (12.3%) MACCE-4P occurred. After multivariable adjustment, higher levels of IL-1β (HR: 1.63; 95% CI: 1.15-2.32), IL-6 (1.72, 1.20-2.46), and hsCRP (1.59, 1.09-2.30) were associated with increased MACCE-4P risk, whereas IL-18 was not. For combined analysis, any 2-biomarker combination from either the IL-1β/IL-6/hsCRP or IL-18/IL-6/hsCRP pathway significantly predicted higher MACCE-4P risk (HR range: 1.84-2.19), with further risk elevation observed for the 3-biomarker combinations (HR: 3.09; 95% CI: 1.80-5.31 for IL-1β pathway; HR: 2.26; 95% CI: 1.24-4.14 for IL-18 pathway). The 4-biomarker combination (IL-1β+IL-6+IL-18+hsCRP) also predicted significantly higher MACCE-4P risk (HR: 2.64; 95% CI: 1.36-5.14). Notably, 3-/4-combined biomarkers demonstrated significant incremental predictive value over single biomarkers. CONCLUSIONS: In patients with MVD, combined assessment of NLRP3-associated inflammatory biomarkers offers significant incremental predictive value beyond individual biomarkers. These findings highlight the importance of integrating multiple inflammatory biomarkers to better identify patients with residual inflammatory risk.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) conducted a cohort in Multivessel coronary artery disease (MVD) (n=1,058). Elevated combination of 4 NLRP3-associated inflammatory biomarkers (IL-1β, IL-6, IL-18, and hsCRP) vs. No elevated biomarkers (0 biomarkers at a high level) was evaluated on MACCE-4P (composite of all-cause death, myocardial infarction, revascularization, and stroke) (HR 2.64, 95% CI 1.36-5.14, p=0.004). The concurrent elevation of all four NLRP3-associated inflammatory biomarkers (IL-1β, IL-6, IL-18, and hsCRP) was associated with a 2.64-fold increased risk of major adverse cardiac events compared to no elevated biomarkers.
Synapse has enriched 10 related papers. Consider them for comparative context: